Pfizer Settles Long-Running Cancer Research IP Suit
Pfizer Inc. has reached a settlement with AntiCancer Inc. to resolve claims the drug giant unlawfully terminated a patent licensing agreement for AntiCancer's research technology following Pfizer's 2009 merger with fellow...To view the full article, register now.
Already a subscriber? Click here to view full article